Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Peer Review reports

Original Submission
19 Jun 2014	Submitted	Original manuscript
19 Jun 2014	Author responded	Author comments - Helen Colhoun
Resubmission - Version 2
19 Jun 2014	Submitted	Manuscript version 2
30 Jun 2014	Author responded	Author comments - Helen Colhoun
Resubmission - Version 3
30 Jun 2014	Submitted	Manuscript version 3
2 Jul 2014	Reviewed	Reviewer Report - Gilles Lambert
13 Jul 2014	Reviewed	Reviewer Report - Baris Gencer
16 Jul 2014	Reviewed	Reviewer Report - Eli Roth
5 Sep 2014	Author responded	Author comments - Helen Colhoun
Resubmission - Version 4
5 Sep 2014	Submitted	Manuscript version 4
Publishing
11 Sep 2014	Editorially accepted
20 Sep 2014	Article published	10.1186/1471-2261-14-121

Back to article page